mins | This voice is AI generated.
Our client needed support for the identification and selection of opportunities to grow and optimize its offerings. Business opportunities in multiple indications were evaluated based on growth potential, client’s current capabilities, and gaps in the portfolio. The complex findings were used as an input to present it through our proprietary “risk and return trade-off matrix” tool. The insights were used to prioritize the opportunities and develop new products targeting Rare diseases, Pain, and Inflammation.
The client narrowed its focus on the selected high potential indications/subindication from the opportunity canvas. The innovator determined the sequence of opportunities and built a future road map based on different scenarios and synergies. FutureBridge enabled client in decision making by addressing following key business questions through robust research methodology.
Pain Pain & Inflammation are common symptoms in various indications, therefore, offer high revenue potential. This makes the space very competitive. On the other hand, despite a limited patient pool, rare diseases are attractive because of the shorter R&D path and ease of approval.
FutureBridge conducted a structured secondary research and focused group discussions across the therapeutic value chain. This included:
FutureBridge provided support to the client to access scientific proof to prioritize and benchmark indications to focus and design strategy for the next decade in a complex therapeutic segment.
FutureBridge continued to support the client by shortlisting potential candidates for the next level of partnering and acquisition assessment and due diligence. In addition, the comprehensive exercise also triggered multiple continuous competition monitoring projects designed specifically for the priority & strategic therapeutic segments.
Share your focus area or question to engage with our Analysts through the Business Objectives service.
Submit My Business ObjectiveOur long-standing clients include some of the worlds leading brands and forward-thinking corporations.
